AIM: To assess the early clinical outcomes of an ICL with a central hole (Hole ICL) implantation for the correction of moderate to high myopia. METHODS: This study evaluated 20 eyes of 20 patients with spherical equivalents of -7.36 ± 2.13 D (mean ± SD) who underwent Hole ICL implantation. Before surgery and at 1 week and 1, 3 and 6 months after surgery, we assessed the safety, efficacy, predictability, stability and adverse events of the surgery. RESULTS: Logarithm of the minimum angle of resolution (logMAR) uncorrected visual acuity and logMAR best spectacle-corrected visual acuity were -0.20 ± 0.12 and -0.25 ± 0.06, respectively, 6 months after surgery. The safety and efficacy indices were 1.13 ± 0.24 and 1.03 ± 0.30, respectively. At 6 months, 95%, and 100% eyes were within ± 0.5 and ± 1.0 D of the targeted correction, respectively. Change in manifest refraction from week 1 to month 6 was 0.06 ± 0.28 D. No significant rise in intraocular pressure (including pupillary block) or a secondary cataract occurred in any case during the period of observation. CONCLUSIONS: Implantation of a newly developed Hole ICL offered good results for all measures of safety, efficacy, predictability and stability for the correction of moderate to high myopic errors, even without peripheral iridectomy, suggesting its viability as a surgical option for the treatment of such eyes.
AIM: To assess the early clinical outcomes of an ICL with a central hole (Hole ICL) implantation for the correction of moderate to high myopia. METHODS: This study evaluated 20 eyes of 20 patients with spherical equivalents of -7.36 ± 2.13 D (mean ± SD) who underwent Hole ICL implantation. Before surgery and at 1 week and 1, 3 and 6 months after surgery, we assessed the safety, efficacy, predictability, stability and adverse events of the surgery. RESULTS: Logarithm of the minimum angle of resolution (logMAR) uncorrected visual acuity and logMAR best spectacle-corrected visual acuity were -0.20 ± 0.12 and -0.25 ± 0.06, respectively, 6 months after surgery. The safety and efficacy indices were 1.13 ± 0.24 and 1.03 ± 0.30, respectively. At 6 months, 95%, and 100% eyes were within ± 0.5 and ± 1.0 D of the targeted correction, respectively. Change in manifest refraction from week 1 to month 6 was 0.06 ± 0.28 D. No significant rise in intraocular pressure (including pupillary block) or a secondary cataract occurred in any case during the period of observation. CONCLUSIONS: Implantation of a newly developed Hole ICL offered good results for all measures of safety, efficacy, predictability and stability for the correction of moderate to high myopic errors, even without peripheral iridectomy, suggesting its viability as a surgical option for the treatment of such eyes.